Table 3. Clinicopathological features and protein expression by HER2 and MYC amplification status.
| Factor (N) | HER2 amplification [N(%)] | OR (95% CI) | MYC amplification [N(%)] | OR (95% CI) | MYC duplication or pol8 [N(%)] | OR (95% CI) | High MYC gain [N(%)] | OR (95% CI) | MYC gain [N(%)] | OR (95% CI) | ||||||
| Negative (HER2/CEP17≤2.2) | Positive (HER2/CEP17>2.2)* | Negative (MYC/CEP8≤2.2) | Positive (MYC/CEP8>2.2)* | Negative (MYC/CEP8<1.3) | Positive (MYC/CEP8≥1.3 or pol8) | Negative (MYC/nucleus<5) | Positive (MYC/nucleus≥5)* | Negative (MYC/nucleus<2.5) | Positive (MYC/nucleus≥2.5)* | |||||||
| Age | ||||||||||||||||
| ≤40 (27) | 17 (14.66) | 10 (8.62) | 0.431 (0.169–1.100) | 25 (21.55) | 2 (1.72) | 0.480 (0.366–8.495) | 5 (4.31) | 22 (18.97) | 0.169 (0.059–0.488)** | 24 (20.69) | 3 (2.59)) | 1.622 (0.432–6.085) | 1 (0.86) | 26 (22.41 | 0.093 (0.012–0.723)** | |
| >40 (89)* | 71 (61.21) | 18 (15.52) | 78 (67.24) | 11 (9.48) | 51 (43.97) | 38 (32.76) | 74 (63.79) | 15 (12.93) | 26 (22.41) | 63 (54.31) | ||||||
| Grade | ||||||||||||||||
| 1/2 (96) | 75 (64.66) | 21 (18.10) | 1.923 (0.681–5.432) | 86 (74.14) | 10 (8.62) | 1.518 (0.378–6.100) | 48 (41.38) | 48 (41.38) | 1.500 (0.563–3.997) | 82 (70.69) | 14 (12.07) | 1.464 (0.426–5.028) | 23 (19.83) | 73 (62.93) | 1.260 (0.383–4.150) | |
| 3 (20)* | 13 (11.21) | 7 (6.03) | 17 (14.66) | 3 (2.59) | 8 (6.90) | 12 (10.34) | 16 (13.79) | 4 (3.45) | 4 (3.45) | 16 (13.79) | ||||||
| Tumor invasion | ||||||||||||||||
| T1/T2 (9) | 7 (6.03) | 2 (1.72) | 1.123 (0.220–5.748) | 7 (6.03) | 2 (1.72) | 0.401 (0.074–2.175) | 5 (4.31) | 4 (3.45) | 1.373 (0.349–5.393) | 7 (6.03) | 2 (1.72) | 0.615 (0.117–3.233) | 1 (0.86) | 8 (6.90) | 0.389 (0.046–3.262) | |
| T3/T4 (107)* | 81 (69.83) | 26 (22.41) | 96 (82.76) | 11 (9.48) | 51 (43.97) | 56 (48.28) | 91 (78.45) | 16 (13.79) | 26 (22.41) | 81 (69.83) | ||||||
| Lymph node metastasis | ||||||||||||||||
| Absent (6) | 4 (3.45) | 2 (1.72) | 0.619 (0.107–3.575) | 5 (4.31) | 1 (0.86) | 0.612 (0.066–5.689) | 4 (3.45) | 2 (1.72) | 2.231 (0.392–12.686) | 5 (4.31) | 1 (0.86) | 0.914 (0.100–8.318) | 2 (1.72) | 4 (3.45) | 1.700 (0.294–8.832) | |
| Present (110)* | 84 (72.41) | 26 (22.41) | 98 (84.48) | 12 (10.34) | 52 (44.83) | 58 (50.00) | 93 (80.17) | 17 (14.66) | 25 (21.55) | 85 (73.28) | ||||||
| Response to therapy | ||||||||||||||||
| Sensitive (50) | 46 (39.66) | 4 (3.45) | 6.571 (2.106–20.509)** | 49 (42.24) | 1 (0.86) | 10.889 (1.365–86.840)** | 30 (25.86) | 20 (17.24) | 2.308 (1.089–4.890)** | 48 (41.38) | 2 (1.72) | 7.680 (1.676–35.199)** | 12 (10.34) | 38 (32.76) | 1.074 (0.451–2.557) | |
| Resistant (66)* | 42 (36.21) | 24 (20.69) | 54 (46.55) | 12 (10.34) | 26 (22.41) | 40 (34.48) | 50 (43.10) | 16 (13.79) | 15 (12.93) | 51 (43.97) | ||||||
| HR expression | ||||||||||||||||
| Negative (62) | 39 (33.62) | 23 (19.83) | 0.173 (0.060–0.497)** | 50 (43.10) | 12 (10.34) | 0.079 (0.010–0.627)** | 21 (18.10) | 41 (35.34) | 0.278 (0.129–0.599)** | 46 (39.66) | 16 (13.79) | 0.111 (0.024–0.507)** | 8 (6.90) | 54 (46.55) | 0.273 (0.108–0.691)** | |
| Positive (54)* | 49 (42.24) | 5 (4.31) | 53 (45.69) | 1 (0.86) | 35 (30.17) | 19 (16.38) | 52 (44.83) | 2 (1.72) | 19 (16.38) | 35 (30.17) | ||||||
| HER2 expression | ||||||||||||||||
| Negative (67) | 62 (53.45) | 5 (4.31) | 10.969 (3.761–31.981)** | 65 (56.03) | 2 (1.72) | 9.408 (1.979–44.721)** | 41 (35.34) | 26 (22.41) | 3.574 (1.636–7.808)** | 65 (56.03) | 2 (1.72) | 15.758 (3.417–72.663)** | 20 (17.24) | 47 (40.52) | 2.553 (0.981–6.642)** | |
| Positive (49)* | 26 (22.41) | 23 (19.83) | 38 (32.76) | 11 (9.48) | 15 (12.93) | 34 (29.31) | 33 (28.45) | 16 (13.79) | 7 (6.03) | 42 (36.21) | ||||||
| MYC expression | ||||||||||||||||
| Negative (80) | 77 (66.38) | 3 (2.59) | 58.333 (15.062–225.913)** | 79 (68.10) | 1 (0.86) | 39.500 (4.883–319.520)** | 53 (45.69) | 27 (23.27) | 21.593 (6.067–76.850)** | 78 (67.24) | 2 (1.72) | 31.200 (6.623–146.981)** | 26 (22.41) | 54 (46.55) | 16.852 (2.187–129.871)** | |
| Positive (36)* | 11 (9.48) | 25 (21.55) | 24 (20.70) | 12 (10.34) | 3 (2.59) | 33 (28.45) | 20 (17.24) | 16 (13.79) | 1 (0.86) | 35 (30.17) | ||||||
| HER2 amplification | ||||||||||||||||
| Negative (88) | – | – | – | 87 (75.00) | 1 (0.86) | 65.250 (7.923–537.398)** | 54 (46.55) | 34 (29.31) | 20.647 (4.603–92.614)** | 87 (75.00) | 1 (0.86) | 134.455 (16.267–1111.302)** | 26 (22.41) | 62 (53.45) | 11.323 (1.461–87.758)** | |
| Positive (28)* | – | – | 16 (13.79) | 12 (10.34) | 2 (1.72) | 26 (22.41) | 11 (9.48) | 17 (14.66) | 1 (0.86) | 27 (23.28) | ||||||
*
Reference group for logistic regression analysis; ** Differentially expressed between groups, p<0.05. N: number of samples; OR: odds ratio; CI: confidence interval. HR: hormone receptor; CEP17: chromosome 17 signals ; CEP8: chromosome 8 signals; pol8: chromosome 8 polysomy.